Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.82 |
| ▸ | CCND1 | P24385 | 4/20 | 0.82 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976386 | 1.00 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL29767815 | 1.00 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL28107377 | 1.00 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL19748097 | 1.00 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL31454116 | 1.00 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL4554026 | 0.98 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL30495581 | 0.98 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL464099 | 0.93 | CDK4 (0.78) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL29374771 | 0.93 | CDK4 (0.78) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL15924634 | 0.91 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113105460-B | Synthesis method of 6-hydroisoindolo [2, 1-alpha ] indole compound | 扬州大学 | 2022-10-25 | — | — | CN | claimed |
| CN-113105460-B | Synthesis method of 6-hydroisoindolo [2, 1-alpha ] indole compound | 扬州大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-110845503-B | Preparation and application of arylamine substituted benzodiindole organic hole transport material | 南京林业大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-110845503-A | Preparation and application of arylamine substituted benzodiindole organic hole transport material | 南京林业大学 | 2020-02-28 | — | — | CN | disclosed |
| US-9464048-B2 | 5-oxo-ETE receptor antagonist compounds | FLORIDA INSTITUTE OF TECHNOLOGY (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-10-30 | — | — | US | disclosed |
| EP-2427430-B1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | UNIV MCGILL (CA) | 2014-09-10 | — | — | EP | disclosed |
| US-8809382-B2 | 5-oxo-ETE receptor antagonist compounds | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-08-19 | — | — | US | disclosed |
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | FLORIDA INSTITUTE OF TECHNOLOGY | 2012-05-17 | — | — | US | disclosed |
| EP-2427430-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2012-03-14 | — | — | EP | disclosed |
| US-4351768-A | CARBONLESS, DUPLICATION, INDOLE DYES | STERLING DRUG INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4343493-A | LEUCO DYES; CARBON-FREE; PRESSURE SENSITIVE ELEMENTS; THERMOSENSITIVITY | STERLING DRUG INC. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4322352-A | Indolyl phthalide compounds | STERLING DRUG INC. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4307018-A | CHROMOGENS FOR COPYING SYSTEMS | STERLING DRUG INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4275121-A | Carbonless duplicating and marking systems utilizing indolyl-substituted furanone color formers | STERLING DRUG INC. (US) | 1981-06-23 | — | — | US | disclosed |
| US-4257954-A | INDOLYL-PHENYLSULFONYL-PHENYL METHANE | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4251446-A | COLOR PRECURSORS | STERLING DRUG INC. (US) | 1981-02-17 | — | — | US | disclosed |
| EP-0022634-A1 | Acylated indole derivatives, processes for their preparation and pharmaceutical compositions and drugs comprising them | TEIJIN LIMITED (JP) | 1981-01-21 | — | — | EP | disclosed |
| US-4189171-A | PRESSURE SENSITIVE, THERMAL AND HECTOGRAPHIC SYSTEMS | STERLING DRUG INC. (US) | 1980-02-19 | — | — | US | disclosed |
| US-4075224-A | 3,5-Bis (indolyl)-5-(indolyl)-2(5H)-furanones | STERLING DRUG INC. (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | CDK4 3457/4885CCND1 4364/4885HTR2A 395/4885 |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | CDK4 3457/4885CCND1 4364/4885HTR2A 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.